Home > Dermatology > Low COVID-19 risk for patients with psoriasis on biologic treatment

Low COVID-19 risk for patients with psoriasis on biologic treatment

Presented By
Dr Jorge Georgakopoulos, University of Toronto, Canada
Conference
WPPAC 2021
Patients with moderate-to-severe psoriasis treated with a biologic drug have a similar or possibly lower risk of contracting COVID-19 compared with the general population (0.3% vs 1.8%) [1]. This was found in a multicentre cohort study from Canada, awarded the ‘Best young researcher poster’ at the WPPAC Congress. These findings can guide physicians in continuing biologic therapy during the pandemic. The COVID-19 pandemic has underlined an urgent need for adequate treatment, especially for people living with psoriatic disease and other chronic illnesses. During these uncertain times, many patients have been inquiring whether they should interrupt their treatment. Previously, Dr Jorge Georgakopoulos (University of Toronto, Canada) and colleagues demonstrated that very few patients (1.1%) discontinued biologic therapy due to concerns regarding COVID-19 complications [2]. Around the same time, the European and American dermatology guidelines were publi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on